Sarrias MR - Search Results

1

The three HveA receptor ligands, gD, LT-alpha and LIGHT bind to distinct sites on HveA.

Sarrias MR, Whitbeck JC, Rooney I, Ware CF, Eisenberg RJ, Cohen GH, Lambris JD. Sarrias MR, et al. Mol Immunol. 2000 Aug;37(11):665-73. doi: 10.1016/s0161-5890(00)00089-4. Mol Immunol. 2000. PMID: 11164894 Free article.

2

Structure, functions, and evolution of the third complement component and viral molecular mimicry.

Sahu A, Sunyer JO, Moore WT, Sarrias MR, Soulika AM, Lambris JD. Sahu A, et al. Among authors: sarrias mr. Immunol Res. 1998;17(1-2):109-21. doi: 10.1007/BF02786436. Immunol Res. 1998. PMID: 9479573 Review.

3

Cloning, structure, and function of two rainbow trout Bf molecules.

Sunyer JO, Zarkadis I, Sarrias MR, Hansen JD, Lambris JD. Sunyer JO, et al. Among authors: sarrias mr. J Immunol. 1998 Oct 15;161(8):4106-14. J Immunol. 1998. PMID: 9780182

4

Inhibition of herpes simplex virus gD and lymphotoxin-alpha binding to HveA by peptide antagonists.

Sarrias MR, Whitbeck JC, Rooney I, Spruce L, Kay BK, Montgomery RI, Spear PG, Ware CF, Eisenberg RJ, Cohen GH, Lambris JD. Sarrias MR, et al. J Virol. 1999 Jul;73(7):5681-7. doi: 10.1128/JVI.73.7.5681-5687.1999. J Virol. 1999. PMID: 10364318 Free PMC article.

5

Complement and innate immunity.

Song WC, Sarrias MR, Lambris JD. Song WC, et al. Among authors: sarrias mr. Immunopharmacology. 2000 Aug;49(1-2):187-98. doi: 10.1016/s0162-3109(00)80303-3. Immunopharmacology. 2000. PMID: 10904117 Free article. Review. No abstract available.

6

Cloning and structure of three rainbow trout C3 molecules: a plausible explanation for their functional diversity.

Zarkadis IK, Sarrias MR, Sfyroera G, Sunyer JO, Lambris JD. Zarkadis IK, et al. Among authors: sarrias mr. Dev Comp Immunol. 2001 Jan;25(1):11-24. doi: 10.1016/s0145-305x(00)00039-2. Dev Comp Immunol. 2001. PMID: 10980316

7

Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg.

Guthridge JM, Rakstang JK, Young KA, Hinshelwood J, Aslam M, Robertson A, Gipson MG, Sarrias MR, Moore WT, Meagher M, Karp D, Lambris JD, Perkins SJ, Holers VM. Guthridge JM, et al. Among authors: sarrias mr. Biochemistry. 2001 May 22;40(20):5931-41. doi: 10.1021/bi0101749. Biochemistry. 2001. PMID: 11352728

8

Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.

Sarrias MR, Franchini S, Canziani G, Argyropoulos E, Moore WT, Sahu A, Lambris JD. Sarrias MR, et al. J Immunol. 2001 Aug 1;167(3):1490-9. doi: 10.4049/jimmunol.167.3.1490. J Immunol. 2001. PMID: 11466369

9

Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.

Guthridge JM, Young K, Gipson MG, Sarrias MR, Szakonyi G, Chen XS, Malaspina A, Donoghue E, James JA, Lambris JD, Moir SA, Perkins SJ, Holers VM. Guthridge JM, et al. Among authors: sarrias mr. J Immunol. 2001 Nov 15;167(10):5758-66. doi: 10.4049/jimmunol.167.10.5758. J Immunol. 2001. PMID: 11698449

10

Studies of structure-activity relations of complement inhibitor compstatin.

Soulika AM, Morikis D, Sarrias MR, Roy M, Spruce LA, Sahu A, Lambris JD. Soulika AM, et al. Among authors: sarrias mr. J Immunol. 2003 Aug 15;171(4):1881-90. doi: 10.4049/jimmunol.171.4.1881. J Immunol. 2003. PMID: 12902490

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

55 results

Search Page